Swiss drugmaker Novartis is abandoning development of its drug fevipiprant in as...
FILE PHOTO: The company's logo is seen at the new cell and gene therapy factory of Swiss drugmaker Novartis in Stein, Switzerland, November 28, 2019. REUTERS/Arnd Wiegmann
ZURICH - Swiss drugmaker Novartis is abandoning development of its drug fevipiprant in asthma after the medicine failed key trials. “The totality of these results do not support further development of fevipiprant in asthma,” the company said on Monday in a statement.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Swiss body considers ban on Swatch unit selling parts - Schweiz am WochenendeA Swatch unit that supplies parts to much of the watch market faces a possible s...
Consulte Mais informação »
Tuberculosis kills more people than any other pathogenic illnessA quarter of the world's population has latent tuberculosis. Only 10% go on to develop symptoms
Consulte Mais informação »
Rayo-Albacete match abandoned after player subjected to 'Nazi' tauntsA Spanish second division soccer match between Rayo Vallecano and Albacete was a...
Consulte Mais informação »